menu
    • menu

    Company profile for Nektar Therapeutics

    NEW Drugs in Dev: 12
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Sharp is a leader in commercial packaging, clinical services, and sterile manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    As a CDMO, Mikart offers integrated CDMO services for Solid Dose & Non-sterile Liquid formulations.

    Virtual Booth

    Contact Supplier

    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Nektar Therapeutics is a research-based development stage biopharmaceutical company that discovers and develops innovative medicines in areas of high unmet medical need. Our R&D pipeline of new investigational drugs includes treatments for cancer and auto-immune disease. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new drug candidates.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Nektar TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    455 Mission Bay Boulevard South San Francisco, CA 94158
    Telephone
    Telephone
    +1 415.482.5300
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.nektar.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Nektar Therapeutics Reports First Quarter 2026 Financial Results
    Nektar Therapeutics Reports First Quarter 2026 Financial Results

    08 May 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/nektar-therapeutics-reports-first-quarter-2026-financial-results-302766188.html

    PR NEWSWIRE
    08 May 2026
    Share Share
    Nektar Therapeutics Reports Inducement Grants Under Nasdaq LR
    Nektar Therapeutics Reports Inducement Grants Under Nasdaq LR

    01 May 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/nektar-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302760464.html

    PR NEWSWIRE
    01 May 2026
    Share Share
    Nektar To Report Q1 Financial Results On May 7, 2026
    Nektar To Report Q1 Financial Results On May 7, 2026

    29 Apr 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/nektar-to-announce-financial-results-for-the-first-quarter-on-thursday-may-7-2026-after-close-of-us-based-financial-markets-302756324.html

    PR NEWSWIRE
    29 Apr 2026
    Share Share
    Nektar Therapeutics Closes $373.8M Public Offering
    Nektar Therapeutics Closes $373.8M Public Offering

    24 Apr 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/nektar-therapeutics-announces-closing-of-373-8-million-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares-302752250.html

    PR NEWSWIRE
    24 Apr 2026
    Share Share
    Nektar Therapeutics Announces Proposed Public Offering
    Nektar Therapeutics Announces Proposed Public Offering

    20 Apr 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7190386

    FIRSTWORD PHARMA
    20 Apr 2026
    Share Share
    Nektar’s long-term Mid-Stage Alopecia Data fuel Phase 3 plans
    Nektar’s long-term Mid-Stage Alopecia Data fuel Phase 3 plans

    20 Apr 2026

    // ENDPOINTS

    https://endpoints.news/nektars-long-term-mid-stage-alopecia-data-fuels-phase-3-plans/

    ENDPOINTS
    20 Apr 2026
    Share Share

    Excipients

    Click here to find the perfect excipient manufacturers by their capabilities

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact Nektar Therapeutics and get a quotation

    Nektar Therapeutics is a supplier offers 6 products (APIs, Excipients or Intermediates).

    Find NKTR-255 DRUG PRODUCT bulk with DMF offered by Nektar Therapeutics

    Find NKTR-255 DRUG SUBSTANCE bulk with DMF offered by Nektar Therapeutics

    Find Amikacin bulk offered by Nektar Therapeutics

    Find Lysine bulk offered by Nektar Therapeutics

    Find Macrogol bulk offered by Nektar Therapeutics

    Find PEG2MAL40K bulk offered by Nektar Therapeutics

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search